Health & Medical Archives | Page 8 of 245 | Be Korea-savvy

Archive by category Health & Medical

RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design

RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, is proud to announce that its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design Concept 2024 in the Medical Devices and Technology Category, recognizing its intuitive pairing of NPWT housed in a patient-friendly design. The Red Dot Awards [...]

Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR

Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR

SHANGHAI, Oct. 15, 2024 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announce that toripalimab (Indian trade name: ZYTORVI®, Hong Kong trade name: LOQTORZI®) has [...]

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare services for all, with a special focus on vulnerable populations in the Americas who are at greater risk of suicide. Through this partnership with the WHO Foundation, [...]

Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent

Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent

Ghent, Belgium, Oct. 14, 2024 (Korea Bizwire) – Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands and Sweden, today announced it has signed a definitive agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey. This acquisition will significantly enhance Ardena’s capabilities in downstream late-stage [...]

Ascom has been awarded a major contract by the Canton of Zurich to install Ascom’s new Security Support System in nine penal institutions

Ascom has been awarded a major contract by the Canton of Zurich to install Ascom’s new Security Support System in nine penal institutions

Baar, Switzerland, 10 October 2024 Ascom is pleased to announce the expansion of its innovative App “Security Support System”, to nine penal institutions in Canton Zurich. The rollout of the first installation in Winterthur’s prison is scheduled for late 2024 and will continue through 2026 to eight additional correctional facilities in Canton Zurich. The entire project [...]

Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery

Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery

Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-marketing agreement with JointVue for its patented OrthoSonic™ 3D Surgery Planning Technology – the only ultrasound device currently on the market to deliver 3D preoperative planning. JointVue’s technology allows surgeons [...]

Curia Commits to SBTi Net-Zero Standard

Curia Commits to SBTi Net-Zero Standard

ALBANY, N.Y., Oct. 08, 2024 (Korea Bizwire) –  Curia, a leading contract research, development and manufacturing organization, today announced its commitment to set near- and long-term company-wide greenhouse gas (GHG) emission reductions in line with science-based net-zero with the Science Based Targets initiative (SBTi). To achieve this goal, Curia will be investing resources over the next [...]

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal women TVB-009P, Teva’s proposed biosimilar to Prolia, showed Phase 3 clinical results in osteoporosis and is part of Teva’s robust biosimilar portfolio – 7 approved biosimilars and 16 in the pipeline – across critical therapeutic areas such [...]

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide’s groundbreaking results from Phase II  study1 Boehringer launches two Phase III studies of survodutide, LIVERAGE in adults with MASH and moderate or advanced fibrosis, and LIVERAGE-Cirrhosis in those with [...]

Curia Unveils Brand Refresh at CPHI WW in Milan

Curia Unveils Brand Refresh at CPHI WW in Milan

The refined brand highlights Curia’s key capabilities and personalized approach across small molecules, generic APIs and biologics ALBANY, N.Y., Oct. 07, 2024 (Korea Bizwire) – Curia, a leading contract research, development and manufacturing organization, today unveiled its refreshed brand. The update introduces refined corporate messaging and a new brand hierarchy, highlighting the breadth of Curia’s [...]